Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy

Research output: Contribution to journalArticle

Abstract

Bexarotene is a third-generation retinoid X receptor-selective retinoid that is widely used for the early treatment of advanced-stage cutaneous T-cell lymphomas. In this report, we describe a case of successful treatment of advanced primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) with oral bexarotene monotherapy. After the administration of oral bexarotene at a dose of 300 mg/m2/day, all skin lesions and lymph nodes regressed, and complete remission was achieved for 1 year. Our case suggested that bexarotene monotherapy could be one of the possible therapies for the treatment of primary cutaneous PTCL-NOS.

Original languageEnglish
Pages (from-to)212-215
Number of pages4
JournalCase Reports in Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - 2018 Jan 19

Keywords

  • Bexarotene monotherapy
  • Cutaneous T-cell lymphomas
  • Primary cutaneous peripheral T-cell lymphoma not otherwise specified
  • Treatment

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy'. Together they form a unique fingerprint.

  • Cite this